View Older Stories
-
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 172c; offers guidance
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $232 at Jefferies
-
Raymond James Starts Jazz Pharmaceuticals (JAZZ) at Outperform
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $232 at Piper Sandler
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
Barclays Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ)
-
Barclays Starts Jazz Pharmaceuticals (JAZZ) at Overweight (earlier)
-
Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 25c
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $230 at Truist Securities
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Needham
-
Boehringer Ingelheim partners with Jazz Pharmaceuticals on breast cancer study
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $263 at BofA Securities
-
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer
-
4Q25/2026 Biotech Earnings Preview: RBC
-
BofA on Jazz (JAZZ): 'We continue to see $1bn+ peak sales potential for zani in 1L GE'
-
Baird's Brian Skorney on Jazz Pharmaceuticals (JAZZ): 'We are buyers on weakness'
-
Jazz Pharmaceuticals reports positive Ziihera cancer trial results
-
RBC on Jazz (JAZZ): 'Downside Move on HERIZON-GEA Data Leak Unwarranted - Zani Regimens Are Clearly Active and Will See Use'
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $219 at Piper Sandler
-
Jazz Pharmaceuticals to present Epidiolex data at epilepsy conference
-
UBS Downgrades Jazz Pharmaceuticals (JAZZ) to Neutral
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Wells Fargo
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $247 at BofA Securities
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $209 at Baird
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $194 at RBC Capital
-
Werewolf Therapeutics' (HOWL) an 'Attractive Investment Opportunity'- Citizens
-
Jazz Pharmaceuticals presents Modeyso data at neuro-oncology meeting
-
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance
-
RBC Capital on Jazz Pharmaceuticals (JAZZ): 'we would be buyers on the potential upcoming positive ph.III zanidatimab data in GEA'
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-TAJS for extensive-stage small cell lung cancer
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $167 at Morgan Stanley
-
Jazz Pharmaceuticals presents Xywav data at medical conferences
-
Piper Sandler Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ)
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Jazz Pharmaceuticals' Modeyso added to NCCN cancer guidelines
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $205 at Truist Securities
-
Jazz Pharmaceuticals (JAZZ) PT Raised at RBC Capital on 'Meaningful Upside' Potential
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals licenses epilepsy drug from Saniona for $42.5M
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $225 at BofA Securities
-
FDA approves Jazz Pharmaceuticals' dordaviprone for rare brain cancer
-
Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 63c
-
Deutsche Bank Starts Jazz Pharmaceuticals (JAZZ) at Buy
-
Jazz Pharmaceuticals names Renee Gala as CEO, Bruce Cozadd to retire
-
Jazz Pharmaceuticals (JAZZ) Receives EU Marketing Authorization for Ziihera
-
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
Jazz Pharmaceuticals (JAZZ) Reports Zepzelca and Atezolizumab Combination Granted FDA Priority Review
-
Jazz Pharmaceuticals (JAZZ) presents phase 4 Xywav data
-
UBS Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)

